Silver Book Fact

Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.

Lindsay R, Pack S, Li Z. Longitudinal Progression of Fracture Prevalence through a Population of Postmenopausal Women with Osteoporosis. Osteoporos Int. 2005; 16(3): 306-12. http://www.ncbi.nlm.nih.gov/pubmed/15455193

Reference

Title
Longitudinal Progression of Fracture Prevalence through a Population of Postmenopausal Women with Osteoporosis
Publication
Osteoporos Int
Publication Date
2005
Authors
Lindsay R, Pack S, Li Z
Volume & Issue
Volume 16, Issue 3
Pages
306-12
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • 30 drugs are currently in development for osteoporosis.  
  • Tools to Prevent Secondary Osteoporosis Fractures are Not Being Used
     
  • A systematic review of osteoporosis therapies found good evidence that many are effective in preventing fractures, but concluded that the data are insufficient to determine if any one therapy is…  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by…